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EDITORIAL COMMENT
Is Programmed Stimulation in
Survivors of Myocardial Infarction
Helpful?*
John P. DiMarco, MD, PHD, FACC
Charlottesville, Virginia
Despite multiple advances in the early management of
myocardial infarction (MI), late mortality among survivors
of the acute episode remains a continuing problem. Numer-
ous protocols have been proposed to “risk-stratify” MI
survivors. Spontaneous and/or inducible ischemia and de-
pressed left ventricular infarction are well-accepted markers
for an adverse prognosis, and several strategies to treat
ischemia and congestive failure have been shown to reduce
mortality (1). A number of electrocardiographic and elec-
trophysiologic risk factors for both sudden death and total
mortality have also been characterized, including frequent or
complex ventricular ectopy, baroreceptor sensitivity, heart
rate variability, T-wave alternans, late potentials on a
signal-averaged electrocardiogram (SAECG), and induc-
tion of ventricular tachycardia (VT) with programmed
ventricular stimulation. Multiple observational studies have
indicated that beta-adrenergic blocking drugs can improve
mortality in MI survivors with one or more of these
findings. However, until recently, studies with antiarrhyth-
mic drugs have yielded either a negative effect (flecainide,
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encainide, moricizine, mexiletine, d-sotalol), no net change
(dofetilide), or inconsistent benefit (amiodarone) (2). More
recent studies of sudden death prophylaxis have focused on
use of implantable cardioverter-defibrillators (ICDs) as
tools to reduce sudden death and total mortality. Random-
ized trials, most notably the Antiarrhythmics Versus Im-
plantable Defibrillators (AVID) trial (3), in patients who
survived an episode of sustained VT or ventricular fibrilla-
tion have shown a significant decrease in mortality in the
group receiving an ICD. Three published trials have eval-
uated ICD implantation for the primary, as opposed to
secondary, prevention of sudden death. The Coronary
Artery Bypass Graft (CABG) Patch Trial (4) found that
ICD implantation did not improve survival among patients
undergoing surgical coronary revascularization. The Multi-
center Automatic Defibrillator Implantation Trial (MA-
DIT) (5) enrolled patients with prior MI, a low left
ventricular ejection fraction and spontaneous nonsustained
and inducible sustained VT. The MADIT showed a highly
significant reduction in total mortality among ICD recipi-
ents. Although the Multicenter Unsustained Tachycardia
Trial (MUSTT) (6,7) was not specifically a trial of ICD
therapy, the lowest mortalities in that trial were observed in
those who eventually received an ICD.
CURRENT STUDY
In this issue of the Journal, Schmitt et al. (8) used pro-
grammed ventricular stimulation after MI to identify po-
tential candidates for prophylactic ICD therapy. They
screened a consecutive series of 1,436 MI survivors at a
single hospital. During the acute phase, .90% of these
patients underwent either a percutaneous coronary interven-
tion or received thrombolytic therapy. In addition, .70%
had a second revascularization procedure the second week
after infarction. Thus, this population resembles the CABG
Patch trial population in that almost all patients were
aggressively revascularized. Patients also underwent a non-
invasive risk-stratification protocol that included measure-
ments of left ventricular ejection fraction, ventricular ectopy,
heart rate variability, and an SAECG; .10 premature
ventricular beats per hour or salvos of ventricular beats were
the criteria used for significant ventricular ectopy. A risk
score was then developed that assigned a value of 3 to
subjects with a left ventricular ejection fraction of ,40%,
and values of 1 to those with ejection fractions between 40%
and 49%, significant ventricular ectopy, abnormal heart rate
variability, or late potentials on the SAECG. A total of 248
patients (17.6%) of the original group of 1,436 had a risk
score of $3. Patients .75 years of age were excluded
according to the study design. Of the remaining 194
patients, 98 (51%) underwent programmed ventricular
stimulation using a standard protocol and criteria. Of these,
21 (22%) developed monomorphic VT in response to
stimulation, and 20 of these 21 went on to receive an ICD.
During follow-up (607 6 424 days), 7 of these 21 patients
with an ICD received therapy that was considered to be
appropriate based on RR interval and stored electrogram
analysis. Among the 77 patients who did not have inducible
monomorphic VT, including 26 who had ventricular fibril-
lation, polymorphic VT, or VT with a cycle length of
,230 ms, there was only one sudden death and no other
arrhythmic events. Arrhythmic events, sudden death, or
appropriate ICD therapy were more common in those with
the lowest ejection fractions and risk scores of 4 or 5.
Despite the fact that over 1,400 patients were screened
initially and the investigators’ careful follow-up of patients
who did not undergo electrophysiologic study, any conclu-
sions we draw from this study must be based on the event
rates in the group of 98 patients who underwent pro-
grammed stimulation. The investigators found a 35% two-
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year occurrence of appropriate ICD therapy in the group
with inducible VT compared with a 4% two-year sudden
death rate in the group with negative or nonspecific re-
sponses to stimulation. These data should be compared with
similar data from MADIT, MUSTT, and CABG Patch. In
MADIT (5), the two-year mortality rate was 35% in the
conventional therapy group, but more than half the deaths
were not classified as sudden or arrhythmic. In MUSTT
(6,7), the two-year cardiac arrest or arrhythmic death rate
among those with inducible VT but off therapy was only
18%. The comparable rate in those without inducible VT
was 12%. In CABG Patch (4,9), there was no difference in
survival with ICD therapy, but a high proportion of the
patients in the ICD group did receive ICD shocks. In that
trial, however, most of the devices used did not have
electrogram or RR interval storage, and it is thought that
many of these shocks were for supraventricular arrhythmias.
The use of an episode of ICD therapy, even when deemed
appropriate based on stored electrogram review, is also
problematic because device intervention in ICD recipients is
more frequent than cardiac arrest or sudden death in
comparable populations without an ICD (10). Although
CABG Patch, MADIT, and MUSTT were conducted, for
the most part, in patients without a very recent MI, the data
from these three, much larger trials indicate that the current
study by Schmitt et al. (8), because of the small number of
patients in the final treatment group, may well overestimate
the predictive value of the electrophysiologic study and the
benefit of ICD treatment.
There is no disagreement that an ICD can terminate
life-threatening ventricular arrhythmias. In many, but per-
haps not all, populations, ICD therapy should prevent
arrhythmic deaths and prolong overall lifespan. However,
larger studies than the one here will be needed to permit
accurate estimates of the clinical applicability, safety, and
acceptance by patients and physicians of such an approach
(11). In addition, studies on the cost-effectiveness of ICD
therapy should include the cost of screening the initial
population with whatever noninvasive and invasive tests that
were used, as well as the cost of the device implant and
follow-up. Prior economic analyses of ICD therapy have
usually not included the potentially substantial costs of
screening (12).
An alternate approach to that proposed by Schmitt et al.
(8) would be to focus solely on an easily identified, high-risk
group, those with the lowest ejection fractions. Even in the
current study, patients with lower ejection fractions had the
highest risk of receiving ICD therapy. In the European
Myocardial Infarct Amiodarone Trial (EMIAT) (13), the
event rate in the group with ejection fractions of #30% was
over twice that in the group with ejection fractions between
30% and 40%. Several studies in which enrollment is based
primarily on ejection fraction are now underway (14).
Simply focusing on patients with the lowest ejection fraction
would certainly be simpler and should be more attractive
from a cost perspective than the multiple test strategy used
in the Schmitt et al. (8) report.
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